Orchestrating Immunity: The Central Role of G Protein–Coupled Receptors

G Protein-Coupled Receptors (GPCRs) in the Immune System

The human genome encodes approximately 800 G protein–coupled receptors (GPCRs), representing a structurally conserved yet functionally diverse superfamily that underpins cellular communication across virtually all physiological systems. GPCRs are broadly classified into several major families based on sequence homology and ligand preference: Class A (rhodopsin-like receptors), the largest group, which responds to small molecules, chemokines, and lipid mediators; Class B (secretin and adhesion receptors), which mediate peptide hormone signaling and cell–cell or cell–matrix interactions; Class C (glutamate-like receptors), which are activated by amino acids and related metabolites; and Class F (Frizzled/Smoothened receptors), which are primarily involved in developmental signaling pathways such as Wnt and Hedgehog. Collectively, these receptors recognize an extensive spectrum of ligands, including amines, peptides, lipids, nucleotides, ions, and environmental stimuli, enabling them to regulate diverse biological processes through canonical G protein–dependent and β-arrestin–mediated signaling pathways.

Within the immune system, more than 100 GPCRs are directly implicated in immune regulation, where they are expressed across both innate and adaptive immune cell populations, including T cells, B cells, macrophages, dendritic cells, neutrophils, and natural killer (NK) cells. These receptors orchestrate critical processes such as leukocyte trafficking, tissue homing, activation, differentiation, and cytokine secretion. Functionally, immune-relevant GPCRs encompass multiple subclasses: chemokine receptors (e.g., CCR and CXCR families) that direct cell migration along chemotactic gradients; lipid-sensing receptors such as sphingosine-1-phosphate (S1P) and prostaglandin receptors that regulate lymphocyte egress and inflammatory tone; purinergic receptors (e.g., adenosine A2A and P2Y receptors) that sense extracellular nucleotides and modulate immune suppression or activation; complement receptors (e.g., C3aR, C5aR) that integrate signals from the complement cascade; formyl peptide receptors that detect pathogen-associated molecular patterns; adhesion GPCRs that mediate cellular interactions within tissues; and protease-activated receptors that respond to proteolytic activity in inflammatory microenvironments.

The ligands for these receptors span multiple biochemical classes, including chemokines, bioactive lipids, nucleotides and nucleosides, peptides and proteins derived from host or microbial sources, complement fragments, and metabolites generated during tissue damage or infection. Through these interactions, GPCRs function as key navigational and regulatory hubs, guiding immune cells to sites of injury or infection, fine-tuning the balance between pro- and anti-inflammatory responses, and coordinating the resolution phase of inflammation. Importantly, GPCR signaling is highly context-dependent, integrating spatial and temporal cues within specific tissue microenvironments, such as inflamed tissues or the tumor microenvironment.

Dysregulation of GPCR signaling networks contributes to a wide spectrum of immune-mediated diseases, including chronic inflammatory disorders, autoimmune diseases, cancer, allergy, and impaired host defense against pathogens. Aberrant receptor expression, ligand overproduction, or biased downstream signaling can lead to pathological immune cell recruitment, sustained inflammation, or immunosuppression. Consequently, GPCRs represent a central communication axis in immune biology and a highly tractable class of therapeutic targets. Their accessibility at the cell surface, combined with advances in ligand design and an improved understanding of receptor signaling complexity, has enabled the development of diverse pharmacologic strategies aimed at modulating immune responses in a disease-specific manner.

GPCR Function in Immune Cells

Functional GPCR subsets are found across multiple different immune cells

• In macrophages, GPCRs such as formyl peptide receptors and complement receptors enhance pathogen recognition and phagocytosis. Prostaglandin and leukotriene receptors regulate the balance between pro- and anti-inflammatory states, guiding macrophage polarization and tissue repair functions. The Rho pathway influences macrophage motility and phagocytic capacity.
• In dendritic cells, chemokine and lysophospholipid receptors govern migration to lymph nodes, crucial for antigen presentation and T cell priming. Purinergic and protease-activated receptors modulate dendritic cell maturation and cytokine secretion, impacting adaptive immunity initiation.
• In T cell subsets, including regulatory T cells (Tregs), cytotoxic T lymphocytes (CTLs), and helper T cells (Th1, Th2, Th17), GPCRs modulate migration, cytokine production, and effector functions. For example, chemokine receptors direct T cell trafficking to lymphoid and inflamed tissues, while prostaglandin receptors can suppress or enhance T cell activation depending on the context. Lysophospholipid receptors influence T cell egress from lymphoid organs, and purinergic receptors modulate T cell survival and differentiation.
• In NK cells, GPCRs play a central role in regulating cell trafficking, activation, and effector function. NK cells express a diverse repertoire of GPCRs, including chemokine receptors such as CXCR1, CXCR3, CXCR4, and CX3CR1, which coordinate their migration to inflamed tissues, tumors, and sites of infection in response to chemokine gradients. Beyond chemotaxis, GPCR signaling influences NK cell cytotoxicity and cytokine production thereby affecting immune synapse formation and degranulation. Lipid-sensing GPCRs, including receptors for sphingosine-1-phosphate and prostaglandins, further regulate NK cell egress from lymphoid tissues and tune their responsiveness within the tumor microenvironment. Collectively, GPCR-mediated pathways are critical for fine-tuning NK cell localization and functional responses, highlighting their potential as therapeutic targets for enhancing anti-viral and anti-tumor immunity.
• In granulocytes, GPCRs regulate key granulocyte functions such as generating reactive oxygen species and activating proteolytic enzymes, which are critical for their cytotoxic response. GPCRs also control granulocyte migration by directing chemotaxis and cell polarization through pathways that influence movement and adhesion. For example, the chemokine receptor family (such as CXCR1 and CXCR2) guides granulocyte migration toward infection sites, while formyl peptide receptors (FPRs) detect microbial peptides to stimulate reactive oxygen species production and bacterial clearance. These signaling pathways also regulate granulocyte gene expression and survival, affecting their differentiation and functional state.

GPCR Signaling Pathways in Immune Cells

GPCR activation triggers multiple intracellular signaling cascades through coupling with distinct G proteins, enabling fine-tuned cellular responses:

• The cAMP pathway, mediated mainly via Gs and Gi proteins, regulates cyclic AMP levels, influencing gene transcription and cellular metabolism. In immune cells, cAMP often acts as an immunomodulatory signal, dampening excessive inflammation.
• The phosphatidylinositol (PI) pathway through Gq proteins leads to activation of phospholipase C, generating second messengers IP3 and DAG, resulting in calcium mobilization and protein kinase C activation crucial for cell activation and cytokine production.
• The beta-gamma (βγ) subunit pathway released upon GPCR activation influences ion channels, kinases, and other signaling molecules, modulating chemotaxis, survival, and respiratory burst activities.
• The Rho pathway, via G12/13 proteins, regulates cytoskeletal dynamics and cellular morphology, essential for migration and phagocytosis.
• The MAP kinase pathway, often downstream of βγ subunits or other intermediates, controls gene expression related to proliferation, differentiation, and inflammatory mediator production.

Drugs Targeting GPCRs in the Immune System

GPCRs are central regulators of immunity. Dysregulation of GPCR signaling contributes to autoimmune disease, chronic inflammation, cancer progression, and infectious disease susceptibility. Accordingly, GPCRs remain highly attractive drug targets, with multiple approved therapies and an expanding clinical pipeline.

Disease Indications

GPCRs play central roles in modulating immune function and inflammation across a variety of disease contexts. In autoimmune disorders and chronic inflammatory conditions, GPCRs influence both immune cell behavior and tissue responses. Beyond chemokine receptors, lipid- and metabolite-sensing GPCRs, such as sphingosine-1-phosphate (S1P) receptors, prostaglandin receptors, and lysophosphatidic acid (LPA) receptors, control lymphocyte trafficking, tissue infiltration, and the production of inflammatory mediators. By fine-tuning these pathways, pharmacologic interventions can limit pathological immune cell recruitment, dampen excessive cytokine release, and restore homeostatic immune regulation, offering potential therapeutic benefit in diseases such as rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease.

In oncology, GPCRs shape the tumor microenvironment and influence immune surveillance. Non-chemokine receptors, including the adenosine A2A receptor and prostaglandin E2 receptors, can suppress cytotoxic T cell and natural killer (NK) cell activity, while other metabolite- and lipid-sensing GPCRs modulate stromal and myeloid cell functions that support tumor progression. Targeting these pathways has emerged as a strategy to enhance anti-tumor immunity, overcome immune suppression, and improve responses to immunotherapies such as checkpoint inhibitors.

Beyond autoimmunity and cancer, GPCRs are key regulators in infectious disease, hematopoiesis, and tissue repair. For example, pharmacologic modulation of S1P or prostaglandin receptors can influence leukocyte egress during infection, while GPCRs that sense lipids and metabolites contribute to the regulation of fibrosis, metabolic inflammation, and regenerative processes. This broad functional versatility underscores the therapeutic potential of GPCR-targeted drugs across diverse immune-related conditions.

Drug Modalities Targeting Immuno-GPCRs

Small-Molecules

• Small-molecule drugs remain the most widely used modality for targeting GPCRs due to their oral bioavailability, tunable pharmacokinetics, and ability to access both orthosteric and allosteric binding sites. In the context of immunology, these molecules include antagonists, agonists, and modulators that regulate receptor activity to either dampen or enhance immune responses. For example, targets of S1P1 receptors, acting as a functional antagonist that sequesters lymphocytes in lymphoid organs, thereby reducing their circulation to inflamed tissues in multiple sclerosis. Similarly, adenosine A2A receptor antagonists block immunosuppressive signaling in T cells and NK cells, enhancing anti-tumor immunity. Other small molecules, such as CXCR4 antagonists, mobilize hematopoietic stem cells by disrupting receptor-ligand interactions. Mechanistically, these compounds may stabilize inactive receptor conformations, prevent ligand binding, or bias signaling toward or away from specific G protein or β-arrestin pathways.

 
Monoclonal Antibodies

• Monoclonal antibodies (mAbs) provide high specificity for GPCRs or their ligands and are particularly effective when immune cell depletion is desired. For instance, an anti-CCR4 antibody, binds the receptor on T regulatory cells and malignant T cells, inducing Fcγ receptor–mediated antibody-dependent cellular cytotoxicity (ADCC). Similarly, antibodies targeting S1P receptors or GPCR ligands can block signaling without activating downstream pathways, offering potent inhibition with reduced off-target effects. Mechanistically, these antibodies may act as competitive antagonists, ligand traps, or induce receptor internalization, and can leverage immune effector functions to deplete receptor-expressing cells.

 
Peptide-Based Drugs

• Peptide therapeutics mimic endogenous GPCR ligands, providing high receptor selectivity while retaining favorable safety profiles. For example, CXCR4-targeting peptides compete with the natural ligand CXCL12, inhibiting chemotaxis of tumor or immune cells and mobilizing hematopoietic stem cells. Lipid-mimetic peptides targeting prostaglandin or S1P receptors can similarly modulate immune cell migration and cytokine production. Peptide ligands often exploit receptor-binding motifs that are difficult to target with small molecules, allowing for precise modulation of receptor activity.

 
Drugs in Clinical Trials Targeting GPCRs in the Immune System

Several GPCR-targeted drugs are currently under clinical investigation for the treatment of immune-mediated diseases and cancer, reflecting the growing recognition of GPCRs as critical regulators of immune function. In autoimmune and inflammatory conditions, S1P receptor modulators have advanced through clinical trials for multiple sclerosis and ulcerative colitis, reducing lymphocyte egress from lymphoid organs and limiting tissue infiltration. In oncology, agents targeting immunosuppressive GPCR pathways, including adenosine A2A receptor antagonists are being evaluated both as monotherapies and in combination with checkpoint inhibitors to enhance T cell and NK cell activity within the tumor microenvironment. Peptide-based inhibitors of CXCR4, are being explored for stem cell mobilization and as adjuncts in cancer therapy to disrupt tumor-promoting immune cell trafficking. Additionally, monoclonal antibodies against GPCRs, including against CCR4, are in clinical use or trials for hematologic malignancies, leveraging Fc-mediated cytotoxicity to selectively deplete pathogenic T cell populations. These examples illustrate the diverse therapeutic strategies being tested, ranging from small molecules to biologics, and underscore the translational potential of immune-targeted GPCR modulation across a spectrum of disease indications.

Table 1. Small Molecule Drugs Targeting Immuno-GPCRs in Clinical Trials

While chemokine receptors have historically dominated GPCR-targeted immunotherapy, increasing attention is being directed toward non-chemokine GPCRs that regulate immune metabolism, resolution of inflammation, and tissue homeostasis. S1P receptor modulators have demonstrated clear clinical success in autoimmune disease, validating GPCR targeting as a viable immunomodulatory strategy. In oncology, blockade of immunosuppressive GPCR pathways such as adenosine A2A and prostaglandin EP4 is emerging as a promising approach to enhance checkpoint inhibitor efficacy. However, challenges remain, including receptor redundancy, compensatory pathways, and the context-dependent effects of GPCR signaling.

Conclusion

GPCRs occupy a central and multifaceted role in the regulation of immunity, integrating extracellular cues into coordinated cellular responses that govern leukocyte trafficking, activation, differentiation, and resolution of inflammation. Beyond classical chemokine signaling, diverse GPCR families, including receptors for lipids, metabolites, nucleotides, and proteases, collectively shape both innate and adaptive immune landscapes across physiological and pathological contexts. This breadth of function, coupled with their cell type–specific expression and dynamic regulation, positions GPCRs as key regulators of immune homeostasis and dysregulation. Importantly, their tractability as drug targets has already yielded clinically successful therapies that modulate immune cell migration and function, while emerging strategies, such as biased agonism, allosteric modulation, offer opportunities to achieve greater precision and reduced toxicity. In the context of cancer, targeting immunoregulatory GPCR pathways, including those governing adenosine, sphingosine-1-phosphate, and prostaglandin signaling, holds particular promise for overcoming tumor-induced immunosuppression and enhancing anti-tumor immunity, either as monotherapies or in combination with established immunotherapies. Continued elucidation of GPCR signaling networks in immune cells will therefore be critical for unlocking new therapeutic avenues and refining strategies to manipulate immune responses in both inflammatory disease and oncology.

References

1. Viola, A., & Luster, A. D. Chemokines and their receptors: drug targets in immunity and inflammation. Annual Review of Pharmacology and Toxicology 48, 171–197 (2008).
2. Weis, W. I., & Kobilka, B. K. The molecular basis of G protein–coupled receptor activation. Annual Review of Biochemistry 87, 897–919 (2018).
3. Cyster, J. G., & Schwab, S. R. Sphingosine-1-phosphate and lymphocyte egress from lymphoid organs. Annual Review of Immunology 30, 69–94 (2012).
4. Ohta, A., & Sitkovsky, M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414, 916–920 (2001).
5. De Clercq, E. AMD3100/CXCR4 inhibitor. Frontiers in Immunology 6, 276 (2015).
6. Hatse, S. CXCR4 antagonists: targeting the tumor microenvironment. Frontiers in Immunology 5, 276 (2014).
7. Allard, B. et al. The adenosine pathway in immuno-oncology. Nature Reviews Clinical Oncology 17, 611–629 (2020).

Disclaimer: This blog post is intended solely for educational and scientific informational purposes. Any mention of therapeutic drug names, including FDA-approved medications, is for the purpose of accurate reporting and discussion of biomedical research and does not constitute medical advice, endorsement, or promotion. Readers should not interpret the content as a recommendation for any specific treatment. Always consult a qualified healthcare professional for medical advice or treatment decisions.

About Marin Biologic Laboratories

Our Recent Publication/Meeting Presentation on Gene Therapy

1. Development of VNX-101, an Adeno-Associated Virus with Less Immunogenicity and Efficient Long-Term Expression of a CD19 T-Cell Engager. Molecular Therapy Methods & Clinical Development, published online July 24, 2025.

3. Cell-Based Potency Assay for Anti-CD3-Anti-CD19 Diabody. Journal of Immunological Methods. 2025. 545-114004.

3. Development of a Pharmacokinetic (PK) Mouse Serum GLP ELISA for an Anti–CD19–AntiCD3 Diabody
bioRxiv 2025.03.19.644217; doi: https://doi.org/10.1101/2025.03.19.644217.

4. American Society of Hematology (ASH) Annual Meeting 2024.
Abstract link: Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager.

Comprehensive Assay Solutions for In Vitro and Cell Based Potency Assays and Pharmacokinetics Studies- Our Expertise

With 30 years of expertise in cell culture, cell-based assays, and preclinical/clinical PK/PD analysis, we specialize in offering assay services essential for a wide variety of therapeutic drug development programs, preclinical studies, IND/BLA applications, and commercialization. Our comprehensive services include both preclinical non-GLP and GLP assays, as well as non-GMP and GMP assays, providing critical support throughout the entire development pipeline.

Watch the following video and explore our latest presentation on the development and validation of potency and pharmacokinetic (PK) assays for AAV vectors, highlighting innovative methodologies and industry-leading expertise.

Download the full presentation: Development of Custom Cell Based and In vitro Potency and Pharmacokinetics (PK) Assays for AAV vectors- Marin biologic Laboratories

Development of Cell-Based Potency Assays: Case Studies and Blogs from Marin Biologic Laboratories (MarinBio)

Drug Discovery & Development Assays Offered by Marin Biologic Laboratories (MarinBio)

• ADME/Tox
• Molecular Biology
• The Art of Cell Culture
• Exosomes
• Stability Services
• Potency Assay
• Gene Therapy Assays
• Immunotherapy Assays
• Antiviral Therapy Assays
• cGMP
• MLR
• Cell Based Assays
• ELISA
• Flow Cytometry
• Protein
• PCR-qPCR
• Immunoassay
• Radioimmunoassay
• GLP
• Transfection
• Cell Therapy Assays
• Targeted Protein Degradation
• Research to Commercialization